Home Healthcare Healthcare Services Asia Pacific Cell and Gene Therapy Manufacturing QC Market

Asia Pacific Cell and Gene Therapy Manufacturing QC Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy), By Scale (Pre-Commercial/R&D Manufacturing, Commercial Scale Manufacturing), By Mode (Contract Manufacturing, In-House Manufacturing), By Workflow (Cell Processing, Cell Banking, Fill & Finish Operations, Vector Production, Others), By Process (Upstream Processes, Downstream Processes), By End User (Pharmaceutical Companies, Biopharmaceutical/Biotechnological Companies, others), By Technology Type (FACS, ELISA, Others), By Country (China, Japan, India, Korea, Australia, Others), Forecasts, 2026-2034

Last Updated: July 08, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Asia Pacific Cell and Gene Therapy Manufacturing QC Market, By Therapy Type 2022 (USD MILLION/ Units)
    1. Cell Therapy
      1. CAR-T
        1. Autologous CAR-T
        2. Allogeneic CAR-T
      2. CAR-NK
      3. B-Cell
      4. Others
    2. Gene Therapy
      1. Viral
        1. AAV
        2. Lentiviral vectors
        3. Other
      2. Non-Viral
  2. Asia Pacific Cell and Gene Therapy Manufacturing QC Market, By Scale 2022 (USD MILLION/ Units)
    1. Pre-commercial/ R&D Manufacturing
    2. Commercial Scale Manufacturing
  3. Asia Pacific Cell and Gene Therapy Manufacturing QC Market, By Mode 2022 (USD MILLION/ Units)
    1. Contract Manufacturing
    2. In-house Manufacturing
  4. Asia Pacific Cell and Gene Therapy Manufacturing QC Market, By Workflow 2022 (USD MILLION/ Units)
    1. Cell Processing
    2. Cell Banking
    3. Fill & Finish Operations
    4. Raw Material Testing
    5. Vector Production
    6. Other Workflows
  5. Asia Pacific Cell and Gene Therapy Manufacturing QC Market, By Process 2022 (USD MILLION/ Units)
    1. Upstream Processes
    2. Downstream Processes
  6. Asia Pacific Cell and Gene Therapy Manufacturing QC Market, By End-User 2022 (USD MILLION/ Units)
    1. Pharmaceutical Companies
      1. Small Size
      2. Medium Size
      3. Large Size
    2. Biopharmaceutical / Biotechnological Companies
      1. Small Size
      2. Medium Size
      3. Large Size
    3. Contract Manufacturing Organizations
      1. Small Size
      2. Medium Size
      3. Large Size
  7. Asia Pacific Cell and Gene Therapy Manufacturing QC Market, By Technology Type 2022 (USD MILLION/ Units)
    1. Fluorescence-Activated Cell Sorting (FACS)
    2. Enzyme-Linked Immunosorbent Assay (ELISA)
    3. Chromatography
    4. Next-Generation Sequencing (NGS)
    5. Polymerase Chain Reaction (PCR)
    6. Others
  8. Regional Asia Pacific Cell and Gene Therapy Manufacturing QC Market
    1. APAC
      1. APAC Asia Pacific Cell and Gene Therapy Manufacturing QC Market By Therapy Type 2022 (USD MILLION/ Units)
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
      2. APAC Asia Pacific Cell and Gene Therapy Manufacturing QC Market By Scale 2022 (USD MILLION/ Units)
        1. Pre-commercial/ R&D Manufacturing
        2. Commercial Scale Manufacturing
      3. APAC Asia Pacific Cell and Gene Therapy Manufacturing QC Market By Mode 2022 (USD MILLION/ Units)
        1. Contract Manufacturing
        2. In-house Manufacturing
      4. APAC Asia Pacific Cell and Gene Therapy Manufacturing QC Market By Workflow 2022 (USD MILLION/ Units)
        1. Cell Processing
        2. Cell Banking
        3. Fill & Finish Operations
        4. Raw Material Testing
        5. Vector Production
        6. Other Workflows
      5. APAC Asia Pacific Cell and Gene Therapy Manufacturing QC Market By Process 2022 (USD MILLION/ Units)
        1. Upstream Processes
        2. Downstream Processes
      6. APAC Asia Pacific Cell and Gene Therapy Manufacturing QC Market By End-User 2022 (USD MILLION/ Units)
        1. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        2. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        3. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
      7. APAC Asia Pacific Cell and Gene Therapy Manufacturing QC Market By Technology Type 2022 (USD MILLION/ Units)
        1. Fluorescence-Activated Cell Sorting (FACS)
        2. Enzyme-Linked Immunosorbent Assay (ELISA)
        3. Chromatography
        4. Next-Generation Sequencing (NGS)
        5. Polymerase Chain Reaction (PCR)
        6. Others
      8. China
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      9. Korea
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      10. Japan
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      11. India
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      12. Australia
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      13. Taiwan
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      14. South East Asia
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      15. Rest of Asia-Pacific
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.